ABSTRACT Background: Supplementation with folic acid (FA) is recommended worldwide before and during early pregnancy because of its proven effect in preventing neural tube defects, but the role of FA after the 12th gestational week (GW) is much less clear. Objective: We investigated maternal folate and homocysteine responses and related effects in the newborn that resulted from continued FA supplementation after the first trimester of pregnancy. Design: Pregnant women, aged 18-35 y, who were attending an antenatal clinic in Northern Ireland with singleton uncomplicated pregnancies and reported taking FA supplements in the first trimester, were randomly assigned at the start of trimester 2 to receive 400 mg FA/d or a placebo capsule.
INTRODUCTION
Conclusive evidence has been available for .20 y that maternal folic acid (FA) 4 supplementation protects against both first occurrence (1) and recurrence (2) of neural tube defects (NTDs) in early pregnancy. Such evidence has led to clear recommendations, which are in place worldwide, that advise women who are planning a pregnancy to take 400 mg FA/d from preconception until the end of the first trimester (3, 4) . Thus, maternal folate recommendations before and in early pregnancy are predominantly focused on preventing NTDs, but the benefits of continued FA supplementation in later pregnancy are not generally recognized.
The important role that folate plays with the progression of pregnancy was recognized in historical reports of the discovery of human folate deficiency that first linked food sources of the vitamin with the treatment of anemia of pregnancy (5) . Both red cell and serum folate concentrations are known to decrease significantly throughout an unsupplemented pregnancy (6, 7) . Clinical folate deficiency (ie, megaloblastic anemia) was reported to occur in #24% of unsupplemented pregnancies in certain parts of Asia, Africa, and South America and in 2.5-5% of those in well-nourished populations (8) . Early clinical deficiency (ie, indicated by bone marrow megaloblastosis) was reported to occur in #25% of unsupplemented pregnancies in the latter countries (8) . However, it is well established that FA supplementation in pregnancy can prevent subclinical folate deficiency and megaloblastic anemia (6, 9, 10) .
The decline in maternal folate status during pregnancy is generally explained by an increase in requirements for folate associated with the growth of fetal, placenta, and maternal tissue. Furthermore, an increased rate of folate catabolism during pregnancy has been shown in rats (11) and humans (12) , which may also contribute to a reduced maternal folate status. Folate is required for DNA synthesis and methylation processes, including the remethylation of homocysteine to methionine, and is the major determinant of plasma homocysteine concentrations (13) . Hyperhomocysteinemia has been associated with increased risk of a number of pregnancy complications including NTDs (14, 15) , preeclampsia (16, 17) , placenta abruption (18) , recurrent early pregnancy loss (19) , low birth weight, and intrauterine growth retardation (20) .
In early pregnancy, there is universal agreement regarding FA recommendations, and there is consistency in the advice to pregnant women from health professionals, even though the health impact of such recommendations may be somewhat limited in European countries without mandatory FA fortification (21) as a result of the generally poor compliance by women (22, 23) . However, after the 12th week of pregnancy, no official FA recommendations exist, and therefore, the advice to pregnant women tends to be varied and inconsistent. The aim of this study was to investigate the effect of continuing FA supplementation after the first trimester of pregnancy on maternal folate and homocysteine responses and related effects in the newborn.
SUBJECTS AND METHODS

Participants
Between September 2005 and December 2006, women in the first trimester of pregnancy who were attending antenatal clinics at the Causeway Hospital, Coleraine, United Kingdom, were invited to participate in the Folic Acid Supplementation in the Second and Third Trimesters (FASSTT) trial. Participants were healthy women with singleton pregnancies, without current pregnancy complications, and aged between 18 and 35 y (ie, on the basis that pregnancy complications are generally more prevalent in women .35 y of age). Women were excluded from participation if they had gastrointestinal, hepatic, renal, or vascular disease, hematologic disorders, epilepsy, a previous pregnancy with an NTD or were the first degree relative of a woman who had a pregnancy with an NTD, or were themselves a sufferer of an NTD. Participants who were taking a medication known to interfere with B vitamin metabolism or those who had undergone in vitro fertilization treatment were also excluded.
On recruitment (at the first antenatal visit), women were asked to complete a screening questionnaire on general health and pregnancy details. As part of the screening process, supplementation usage was discussed with particular emphasis on FA and other B vitamin supplements. Information was collected on the name of the supplement, the FA content of the supplement, when the supplement was started, and the frequency of its usage. Only women who had taken FA supplements at a dose of 400 mg/d as recommended in the first trimester of pregnancy were eligible for inclusion, and they provided a nonfasting blood sample. Ethical approval was granted by the Office for Research Ethics Committees Northern Ireland (reference 05/Q2008/21), and informed consent was obtained from each participant on recruitment.
Intervention and random assignment
The study was conducted as a double-blinded, randomized controlled trial. The sample size was estimated by using mean (6SD) red cell folate and homocysteine concentrations in women who had taken (or not taken) FA supplements from our previous observational study of pregnant women in Northern Ireland (28) . We estimated that a sample size of 60 subjects per group would be able to discriminate a difference in homocysteine concentration of 0.5 mmol/L between placebo and treatment groups with a power of 80% at a = 0.05 (29) . This sample size was calculated on the basis of the lower range of the expected effect size observed in the previous investigation, which would have maximized the capability in the current study to detect any clinically meaningful changes in plasma homocysteine as a result of FA intervention in late pregnancy.
Participants at the start of the second trimester were stratified into tertiles of homocysteine concentrations (from the blood sample at recruitment), and women in each stratum were then randomly assigned to receive either 400 mg FA/d or a placebo until the end of pregnancy. FA and placebo tablets were identical in color, size, and shape. To ensure that both the researcher and participant remained blind to treatment-group allocation, the random assignment was conducted by a staff member who was not involved in the study. To maximize compliance, vitamin supplements were distributed every 4 wk to the participant's home in 7-d pillboxes with instructions to take one tablet each morning. The pillboxes were collected, and the number of unused tablets was recorded to monitor compliance.
Blood sampling and laboratory analysis
A nonfasting blood sample was collected from each participant at the time of recruitment [on average, at the 14th gestational week (GW)] and again at the 36th GW. Cord blood was also collected during delivery after placenta expulsion. All samples were kept refrigerated on collection and processed within 4 h (apart from cord blood samples, which were processed within 24 h of collection); aliquots were stored at 2808C for batch analysis at the end of the study. Blood samples were analyzed by using a microbiological assay for serum and red cell folate (24) and serum vitamin B-12 (25) and fluorescence polarization immunoassay for plasma homocysteine (26) .
For all assays, samples were analyzed blind in #18 mo of collection, and quality control was provided by repeated analysis of stored batches of pooled samples that covered a wide range of values. Intraassay and interassay CVs were #8.2% for folate, #10.4% for vitamin B-12, and #2.5% for homocysteine. The methylenetetrahydrofolate reductase (MTHFR) 677C.T genotype was identified by using polymerase chain reaction amplification followed by HinF1 restriction digestion (27) .
Dietary analysis
Dietary data were collected during the second trimester of pregnancy. Intakes of the relevant B vitamins were evaluated by using a 4-d food diary (which included 2 weekdays and 2 weekend days) in combination with a food-frequency questionnaire. The food-frequency questionnaire was designed primarily to measure intakes of foods fortified with B vitamins and included 29 food groups or specific branded products, such as ready-to-eat breakfast cereals, breakfast cereal bars, breads, and fat spreads. A dietary analysis was carried out with a nutritional software package (WISP version 3.0; Tinuviel Software) that was specifically modified to include the most up-to-date nutrient values for fortified foods and to enable the generation of separate values for the natural content of folate in food and FA added to foods, which were combined to provide total folate intake values.
Statistical analysis
A statistical analysis was performed with the Statistical Package for the Social Sciences software (version 20.0; SPSS UK Ltd). Data on blood concentrations of B vitamins were log transformed before analysis for normalization purposes. For continuous variables, differences between groups were examined by using an independent t test. For categorical variables, differences were examined by using the chi-square test. Responses to the FA intervention were calculated as the difference between posttreatment and pretreatment values and were examined by using a within-between repeated-measures ANOVA. The betweenparticipant factor was the intervention group (placebo compared with FA), and the within-participant factor was time (before compared with after intervention). In all analyses, P , 0.05 was considered significant.
RESULTS
Of the total available sample of 296 pregnant women (Figure 1 ), 248 women (84%) reported taking FA supplements at any time in the first trimester. Of these subjects, 22 women were excluded because they were taking FA at a dose higher than the recommended dose of 400 mg/d. The remaining 226 women fulfilled the inclusion criteria and were deemed eligible for investigation. Of these subjects, 36 women withdrew before random assignment, which left a total of 190 participants who commenced the FASSTT trial. Of women who started the trial, a total of 119 participants completed the intervention; all participants randomly assigned to treatment who did not complete the trial were accounted for, and the specific reasons for any dropout are presented in Figure 1 . There were no significant differences in red cell or serum folate concentrations between women randomly assigned to treatment who completed the trial and women who dropped out (data not shown). On the basis of pill counts from returned pillboxes, an overall compliance rate of 93% was observed in women who completed the trial.
When sampled at the 14th GW (preintervention), no significant differences in general participant characteristics, including BMI (in kg/m 2 ), smoking status, or parity, were observed between the 2 treatment groups ( Table 1) . Likewise, there were no significant differences in dietary intakes or blood concentrations of folate, vitamin B-12, or homocysteine. The frequency of the MTHFR 677TT genotype was also not different between the placebo and treatment groups, which was of relevance because of the potential confounding effect of this genotype, which is typically associated with lower folate and higher homocysteine concentrations. Dietary intakes generally compared favorably with current reference values in the United Kingdom (30).
Responses to intervention with either FA (400 mg/d) or placebo from the 14th to 34th GWs were examined ( Table 2) . Posttreatment concentrations of serum and red cell folate were significantly lower, and plasma homocysteine concentrations were significantly higher, in the placebo than FA-treated groups. A significant time 3 treatment interaction was observed for serum folate (P , 0.001), red cell folate (P , 0.001), and plasma homocysteine (P = 0.006) (within-between repeated-measures ANOVA). Serum vitamin B-12 concentrations decreased significantly in both treatment groups from GWs 14-36 (P , 0.001; data not shown), but there was no significant effect of treatment. From GWs 14-36, serum folate decreased by 56% in unsupplemented women, whereas red cell folate decreased by 21%, and plasma homocysteine increased by 1 mmol/L (Figure 2) . However, FA supplementation prevented the significant changes in serum folate and plasma homocysteine and increased red cell folate concentrations between GWs 14 and 36.
A comparison of cord blood B vitamin concentrations between treatment groups showed significantly higher serum and red cell folate concentrations in infants of mothers supplemented with FA, whereas neither homocysteine nor vitamin B-12 concentrations were significantly different ( Table 3) . We detected no significant differences between groups in general neonatal characteristics, such as gestation at labor, birth weight, length, or head circumference; however, the trial was not powered to investigate these effects.
DISCUSSION
In this randomized controlled trial conducted in women who had taken FA in the first trimester of pregnancy, results showed that continuing FA supplementation at a dose of 400 mg/d in the second and third trimesters produced a significant increase in maternal red cell folate and cord blood folate concentrations and prevented the decline in serum folate and elevation in homocysteine concentrations that otherwise occur with the progression of pregnancy. To our knowledge, this is the first randomized trial to report that continued supplementation with FA prevented an increase in later pregnancy of the plasma homocysteine concentration by 1 mmol/L, with potential beneficial effects for pregnancy outcome. 2 Differences between groups were assessed by using an independent t test (continuous variables) or chi-square test (categorical variables).
3 Genotype for the methylenetetrahydrofolate reductase (MTHFR) 677C.T polymorphism; CC (wild type), CT (heterozygous), and TT (homozygous mutant). 4 Conversion to dietary folate equivalents is as follows: micrograms of natural food folate plus 1.7 3 micrograms of added folic acid; thus, dietary folate equivalent values were 347 mg/d (placebo group) and 376 mg/d (treatment group). 1 All values are means 6 SDs. Folate values were converted from micrograms per liter to nanomoles per liter by using a conversion factor of 2.267. Preintervention refers to the 14th gestational week; postintervention refers to 36th gestational week. All pregnant women reported to have taken folic acid in the first trimester, including some who had commenced supplementation before conception. Response was calculated as the difference between postintervention and preintervention values. FASSTT, Folic Acid Supplementation in the Second and Third Trimesters.
2 Time 3 treatment interaction (within-between repeated-measures ANOVA) comparing the effect of treatment with placebo over time.
Folate is critically required for fetal, placental, and maternal tissue growth during pregnancy. Maternal folate status is known to be compromised in unsupplemented pregnancy (6, 7), whereas high-dose FA prevents the decline in blood folate (9, 10) . In this trial, participants in the placebo group had significantly decreased serum and red cell folate concentrations by the third trimester despite taking FA supplements (400 mg/d) in the first trimester. However, continued supplementation with FA prevented the decrease in serum folate and led to an increase in red cell folate. This inconsistent pattern between serum and red cell folate responses was in line with previous reports of differences in alterations of these indexes during pregnancy (6) and probably reflected the fact that they represent 2 distinct folate pools. Serum folate is the earliest indicator of altered folate exposure, whereas red cell folate responds more slowly to depletion or repletion and better reflects long-term folate status. An examination of serum folate concentrations at 36 GWs showed that only 2% of women in the FA-treatment group compared with 11% of women in the placebo group had values that fell below the cutoff concentration of 7.0 nmol/L, which was previously suggested to indicate subclinical folate deficiency in later pregnancy (31) . Thus, continuing to take FA at a supplemental dose of 400 mg/d can prevent folate decline and maintain a more optimal maternal folate status throughout pregnancy. In addition, there may be benefits for a subsequent pregnancy of continuing FA supplementation, particularly for women with increased parity who appear to be less compliant than primigravidae women with current FA recommendations aimed at preventing NTDs in early pregnancy, as reported previously by ourselves and others (22, 23) . Thus, by optimizing maternal folate status, continued FA supplementation may be beneficial for not only the current but also a subsequent pregnancy, especially in women with a short interval between pregnancies.
Plasma homocysteine concentrations are known to be 50-60% lower in pregnant than nonpregnant women (32) and increase in later pregnancy (28) , although previous observational studies have linked reported FA usage beyond the first trimester with lower pregnancy homocysteine concentrations (28, 33) . The current randomized trial provides firm evidence that the expected increase in homocysteine that otherwise occurs in later pregnancy is preventable by continuing FA supplementation in the second and third trimesters. Homocysteine concentrations have been reported to be lowest during the second trimester of pregnancy and gradually increase toward the end of the third trimester to concentrations similar to those of nonpregnant women (28) . Thus, the homocysteine concentrations measured in the current study at 36 GWs were generally reflective of nonpregnant concentrations and could have, in turn, been relevant to the pregnancy outcome. One large retrospective study showed that higher plasma homocysteine concentrations in nonpregnant Norwegian women were strongly related to adverse outcomes and complications including preeclampsia, premature delivery, and very low birth weight in 14,492 previous pregnancies (20) . The observed dose-response relations between plasma homocysteine and the reported pregnancy outcomes were shown to be within the homocysteine concentration range of 5-15 mmol/L, which was similar to homocysteine concentrations of FASSTT participants, and suggested that the lowering of homocysteine by 1 mmol/L with FA treatment in the current trial may have been associated with decreased risk of adverse outcomes. Likewise, other studies have associated elevated pregnancy concentrations of homocysteine with various complications and adverse pregnancy outcomes (16, 17, 34, 35) . However, it is not known whether the relation between elevated homocysteine and pregnancy complications reported in these and the aforementioned study (20) is causal in nature. If a causal link is confirmed, the decrease in homocysteine by continuing FA usage may prove to be beneficial. However, some consider the increase in homocysteine at the end of pregnancy to be a natural phenomenon that prepares the uterus for labor by stimulating the contractility of uterine cells (36) ; in this case, any decrease in homocysteine might not be so advantageous. Additional studies are required to clarify the significance of homocysteine concentrations in later pregnancy and the potential preventative effect of intervention with FA in relation to adverse pregnancy outcomes.
Because of its relation with mortality and morbidity, birth weight is considered to be of major importance for pregnancy outcome (37) . Observational studies have generally shown positive associations between maternal folate status and birth weight (38) (39) (40) , whereas homocysteine concentration has been inversely linked with birth weight (33, 41, 42) . However, intervention trials that examined the effect of FA have been inconclusive, with some studies that observed a positive effect on birth weight (10, 43, 44) and other studies that showed no effect (9, 45) . Possible reasons for the inconsistency between studies include differences in the study design or interactions with other nutrients. We showed no effect of continued FA supplementation on birth weight, which is a finding that may be explained by the relatively small sample size and, thus, potentially insufficient statistical power to observe a small effect on birth weight, given that our power calculations were based on detecting differences in homocysteine concentrations and not birth weight. However, the lack of any trend toward a positive effect in the FA-treated group makes this explanation unlikely. A more likely explanation for the lack of effect on birth weight was that it was related to the high folate status at baseline in our sample as a result of the study design, which excluded any woman who was not taking FA during the first trimester. If there is an effect of FA supplementation during pregnancy on birth weight, it may possibly only be observed in the face of more generalized maternal folate depletion (10) .
Despite the limitation that this study was conducted in a single center, its strength was that it was a double-blinded randomized trial in a well-characterized cohort and, therefore, could clearly show the effects of supplemental FA at a dose of 400 mg/d, which was administered in addition to estimated dietary intakes of 290 mg FA/d (or 360 mg FA/d when expressed as the dietary folate equivalents). In addition, although we conducted the trial in a region without mandatory FA fortification, FA-fortified foods were regularly consumed by the majority of our sample, which was consistent with a previous report (46) from this region in which FA fortification is permitted on a voluntary basis. Therefore, FA intakes were comparable with countries where mandatory FA fortification is in place and, thus, enhanced the generalizability of the results (47) . Furthermore, the trial left open the opportunity to conduct follow-up studies of the effects of FA supplementation in pregnancy on health outcomes of the offspring, which is an area of current interest because of the role of folate in key epigenetic mechanisms such as DNA and histone methylation, which, in turn, are involved in the control of gene expression (48) . Emerging evidence shows that the human in utero environment can affect these processes with long-term consequences for the offspring (49-51), but thus far, data are scarce.
In conclusion, continuing FA supplementation after the first trimester of pregnancy can prevent the decline in both serum folate and red cell folate concentrations and the increase in plasma homocysteine concentrations that otherwise occur by the later stages of pregnancy. Additional investigations are required to confirm whether these effects have benefits for pregnancy outcomes and early childhood.
We acknowledge the contributions of patients who volunteered to participate in the study and the antenatal staff at the Causeway Hospital.
The authors' responsibilities were as follows-HM: was the principal investigator and is the guarantor; B McNulty: executed the study, conducted the analysis, and wrote the first draft of the manuscript; KP, JMS, B Marshall, JD, and HM: planned, designed, and supervised the study; MW and AMM: contributed to the dietary and laboratory analyses; and all authors: were involved in the data interpretation, manuscript revisions, and final drafting of the manuscript. None of the authors had a conflict of interest. 2 Differences between groups were compared by using an independent t test after log transformation of data for normalization purposes (continuous variables) or chi-square test (categorical variables).
